Ausgabe 1/2016
Inhalt (24 Artikel)
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini, Cindy Serdjebi, Godefridus J. Peters, Elisa Giovannetti
Combinational strategies of metformin and chemotherapy in cancers
Hui-Hui Zhang, Xiu-Li Guo
Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
Jared M. Campbell, Emma Bateman, Matthew D. Stephenson, Joanne M. Bowen, Dorothy M. Keefe, Micah D. J. Peters
A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib
Vikram Malhi, Dawn Colburn, Sarah J. Williams, Cornelis E. C. A. Hop, Mark J. Dresser, Priya Chandra, Richard A. Graham
Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1
Jiao Mo, Min Kang, Jun-Xian Ye, Jing-Bo Chen, Hong-bin Zhang, Chen Qing
Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
D. de Wit, T. C. Schneider, D. J. A. R. Moes, C. F. M. Roozen, J. den Hartigh, H. Gelderblom, H. J. Guchelaar, J. J. van der Hoeven, T. P. Links, E. Kapiteijn, N. P. van Erp
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors
Shivaani Kummar, Alice Chen, Martin Gutierrez, Thomas D. Pfister, Lihua Wang, Christophe Redon, William M. Bonner, William Yutzy, Yiping Zhang, Robert J. Kinders, Jiuping Ji, Deborah Allen, Joseph M. Covey, Julie L. Eiseman, Julianne L. Holleran, Jan H. Beumer, Larry Rubinstein, Jerry Collins, Joseph Tomaszewski, Ralph Parchment, Yves Pommier, James H. Doroshow
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma
Oliver E. Bechter, Herlinde Dumez, Jo Costermans, Kevin Punie, Karl Hsu, Jean-François Dedieu, Anne-Frédérique Ghuysen, Elisa Francesconi, Jyoti Sharma, Li Liu, Patrick Schöffski
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma
Hironaga Satake, Makoto Tahara, Satoshi Mochizuki, Ken Kato, Hiroki Hara, Tomoya Yokota, Naomi Kiyota, Takayuki Kii, Keisho Chin, Sadamoto Zenda, Takashi Kojima, Hideaki Bando, Tomoko Yamazaki, Satoru Iwasa, Yoshitaka Honma, Satoru Hamauchi, Takahiro Tsushima, Atsushi Ohtsu
A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I
Andréia Cristina de Melo, Rachele Grazziotin-Reisner, Felipe Erlich, Mariane S. Fontes Dias, Giulliana Moralez, Michel Carneiro, Álvaro Henrique Ingles Garces, Flávia Vieira Guerra Alves, Bruna Novaes Neto, Mateus Fuchshuber-Moraes, Juliane Morando, Guilherme Suarez-Kurtz, Carlos Gil Ferreira
Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation
Takaya Yamashita, Naohito Fujishima, Masatomo Miura, Takenori Niioka, Maiko Abumiya, Yoshinori Shinohara, Kumi Ubukawa, Miho Nara, Masumi Fujishima, Yoshihiro Kameoka, Hiroyuki Tagawa, Makoto Hirokawa, Naoto Takahashi
UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou, Yong Tang
Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals
Emma C. Martin, Leon Aarons, James W. T. Yates
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
Kezban Nur Pilancı, Sezer Saglam, Alper Okyar, Serap Yucel, Zeliha Pala-Kara, Cetin Ordu, Esat Namal, Rumeysa Ciftci, Ulkuhan Iner-Koksal, Esra Kaytan-Saglam
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency
Muhammad Wasif Saif, Robert B. Diasio
Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites
Amit Mahipal, Jason Klapman, Shivakumar Vignesh, Chung S. Yang, Anthony Neuger, Dung-Tsa Chen, Mokenge P. Malafa
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R. Hess, Javier Munoz, Naifa L. Busaidy, Jennifer J. Wheler, Filip Janku, Gerald S. Falchook, David S. Hong, Funda Meric-Bernstam, Mouhammed Amir Habra, Aung Naing
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment
Frank Bridoux, Nianhang Chen, Stephane Moreau, Bertrand Arnulf, Eric Moumas, Julie Abraham, Estelle Desport, Arnaud Jaccard, Jean Paul Fermand
Effect of renal function on pemetrexed-induced haematotoxicity
Yosuke Ando, Takahiro Hayashi, Moeko Ujita, Sumie Murai, Hideki Ohta, Kaori Ito, Teppei Yamaguchi, Minori Funatsu, Yoshiaki Ikeda, Kazuyoshi Imaizumi, Kenji Kawada, Kimio Yasuda, Shigeki Yamada
RETRACTED ARTICLE: Atrial natriuretic peptide protects against cisplatin-induced granulocytopenia
Takashi Nojiri, Hiroshi Hosoda, Masahiro Zenitani, Takeshi Tokudome, Toru Kimura, Koichi Miura, Mikiya Miyazato, Meinoshin Okumura, Kenji Kangawa
Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma
Michinori Ogura, Takashi Ishida, Kunihiro Tsukasaki, Takeshi Takahashi, Atae Utsunomiya
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours
Sebastiaan C. Goulooze, Peter Galettis, Alan V. Boddy, Jennifer H. Martin
Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors
Ian J. Cohen